BR112014005793A2 - compostos inibidores de enzimas - Google Patents
compostos inibidores de enzimasInfo
- Publication number
- BR112014005793A2 BR112014005793A2 BR112014005793A BR112014005793A BR112014005793A2 BR 112014005793 A2 BR112014005793 A2 BR 112014005793A2 BR 112014005793 A BR112014005793 A BR 112014005793A BR 112014005793 A BR112014005793 A BR 112014005793A BR 112014005793 A2 BR112014005793 A2 BR 112014005793A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyridin
- chlorophenyl
- pyrazolo
- pyrrolo
- piperidin
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 102000004190 Enzymes Human genes 0.000 title abstract 2
- 108090000790 Enzymes Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 abstract 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 abstract 2
- YTYICXYLUBLDHM-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-[1-(pyridin-3-ylmethyl)piperidin-4-yl]pyrazolo[3,4-c]pyridine Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(C2CCN(CC=3C=NC=CC=3)CC2)=N1 YTYICXYLUBLDHM-UHFFFAOYSA-N 0.000 abstract 1
- QATYRYIZQCZJPK-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-piperidin-4-ylpyrrolo[2,3-c]pyridin-4-ol Chemical compound C1=2C(O)=CN=CC=2N(C=2C=CC(Cl)=CC=2)C=C1C1CCNCC1 QATYRYIZQCZJPK-UHFFFAOYSA-N 0.000 abstract 1
- VKIWDHXNHBXEIH-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C(C1=CC=NC=C11)=NN1C1=CC=C(Cl)C=C1 VKIWDHXNHBXEIH-UHFFFAOYSA-N 0.000 abstract 1
- IMZSHOZQEKPUQG-UHFFFAOYSA-N 1-[4-(fluoromethyl)phenyl]-3-(oxan-4-yl)pyrazolo[3,4-c]pyridine Chemical compound C1=CC(CF)=CC=C1N1C2=CN=CC=C2C(C2CCOCC2)=N1 IMZSHOZQEKPUQG-UHFFFAOYSA-N 0.000 abstract 1
- BKCPIIKZPOOFMV-UHFFFAOYSA-N 1-[4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]-4-(dimethylamino)butan-1-one Chemical compound C1CN(C(=O)CCCN(C)C)CCC1C(C1=CC=NC=C11)=CN1C1=CC=C(Cl)C=C1 BKCPIIKZPOOFMV-UHFFFAOYSA-N 0.000 abstract 1
- XLMWNMLTMRLNHE-UHFFFAOYSA-N 2-[4-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl]ethanol Chemical compound OCCC1COCCN1C(C1=CC=NC=C11)=NN1C1=CC=C(Cl)C=C1 XLMWNMLTMRLNHE-UHFFFAOYSA-N 0.000 abstract 1
- ZXMLQCJUWUMPIR-UHFFFAOYSA-N 2-[4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]ethanamine Chemical compound C1CN(CCN)CCC1C(C1=CC=NC=C11)=CN1C1=CC=C(Cl)C=C1 ZXMLQCJUWUMPIR-UHFFFAOYSA-N 0.000 abstract 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 abstract 1
- DHVIHXOUWLISGQ-UHFFFAOYSA-N 4-[1-(4-methylphenyl)pyrrolo[2,3-c]pyridin-3-yl]morpholine Chemical compound C1=CC(C)=CC=C1N1C2=CN=CC=C2C(N2CCOCC2)=C1 DHVIHXOUWLISGQ-UHFFFAOYSA-N 0.000 abstract 1
- YZXLJBAURSYRBM-UHFFFAOYSA-N 5-amino-1-[4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]pentan-1-one Chemical compound C1CN(C(=O)CCCCN)CCC1C(C1=CC=NC=C11)=CN1C1=CC=C(Cl)C=C1 YZXLJBAURSYRBM-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- AHSBRNLPKIICIU-CQSZACIVSA-N [(3r)-4-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl]methanol Chemical compound OC[C@@H]1COCCN1C(C1=CC=NC=C11)=NN1C1=CC=C(Cl)C=C1 AHSBRNLPKIICIU-CQSZACIVSA-N 0.000 abstract 1
- KRGICSYONBDZHH-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]piperidin-2-yl]-piperazin-1-ylmethanone Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(N2C(CCCC2)C(=O)N2CCNCC2)=N1 KRGICSYONBDZHH-UHFFFAOYSA-N 0.000 abstract 1
- UQPLRGBMLZFBEM-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl]-morpholin-4-ylmethanone Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(N2CCC(CC2)C(=O)N2CCOCC2)=N1 UQPLRGBMLZFBEM-UHFFFAOYSA-N 0.000 abstract 1
- ZPDQAZMDJNHKIP-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)pyrazolo[3,4-c]pyridin-3-yl]piperidin-4-yl]-piperazin-1-ylmethanone Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(N2CCC(CC2)C(=O)N2CCNCC2)=N1 ZPDQAZMDJNHKIP-UHFFFAOYSA-N 0.000 abstract 1
- HYQSSECHZGDUAQ-UHFFFAOYSA-N [4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]-(1,4-diazepan-1-yl)methanone Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(C2CCN(CC2)C(=O)N2CCNCCC2)=C1 HYQSSECHZGDUAQ-UHFFFAOYSA-N 0.000 abstract 1
- HUUGOXRVWATWEV-UHFFFAOYSA-N [4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]-morpholin-4-ylmethanone Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(C2CCN(CC2)C(=O)N2CCOCC2)=C1 HUUGOXRVWATWEV-UHFFFAOYSA-N 0.000 abstract 1
- NMUZEXQMQNXYNZ-UHFFFAOYSA-N [4-[1-(4-chlorophenyl)pyrrolo[2,3-c]pyridin-3-yl]piperidin-1-yl]-piperazin-1-ylmethanone Chemical compound C1=CC(Cl)=CC=C1N1C2=CN=CC=C2C(C2CCN(CC2)C(=O)N2CCNCC2)=C1 NMUZEXQMQNXYNZ-UHFFFAOYSA-N 0.000 abstract 1
- CYIDIYZCFGLYSZ-UHFFFAOYSA-N [4-[1-(4-methylphenyl)pyrazolo[3,4-c]pyridin-3-yl]morpholin-2-yl]methanol Chemical compound C1=CC(C)=CC=C1N1C2=CN=CC=C2C(N2CC(CO)OCC2)=N1 CYIDIYZCFGLYSZ-UHFFFAOYSA-N 0.000 abstract 1
- NIYSVSJNDYBCLQ-UHFFFAOYSA-N [4-[1-(4-methylphenyl)pyrazolo[3,4-c]pyridin-3-yl]morpholin-3-yl]methanol Chemical compound C1=CC(C)=CC=C1N1C2=CN=CC=C2C(N2C(COCC2)CO)=N1 NIYSVSJNDYBCLQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- -1 n-butyl-1- (4-chlorophenyl) -N-methyl-1H-pyrazolo [3,4-c] pyridin-3-amine Chemical compound 0.000 abstract 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2011/065967 WO2013037411A1 (en) | 2011-09-14 | 2011-09-14 | New enzyme inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014005793A2 true BR112014005793A2 (pt) | 2017-03-28 |
Family
ID=44677871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014005793A BR112014005793A2 (pt) | 2011-09-14 | 2011-09-14 | compostos inibidores de enzimas |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9150574B2 (enExample) |
| EP (1) | EP2755974A1 (enExample) |
| JP (1) | JP5796130B2 (enExample) |
| CN (1) | CN103889983B (enExample) |
| AU (1) | AU2011376717A1 (enExample) |
| BR (1) | BR112014005793A2 (enExample) |
| CA (1) | CA2847193A1 (enExample) |
| EA (1) | EA201490451A1 (enExample) |
| IL (1) | IL231353A0 (enExample) |
| IN (1) | IN2014DN01883A (enExample) |
| SG (1) | SG11201400277VA (enExample) |
| WO (1) | WO2013037411A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201304526D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| GB201304527D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
| US20160113893A1 (en) | 2013-06-12 | 2016-04-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| GB201416446D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New enzyme inhibitor compounds |
| GB201416444D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New compounds |
| GB201507031D0 (en) * | 2015-04-24 | 2015-06-10 | Proximagen Ltd | New pharmaceutical salt forms |
| WO2017098236A1 (en) | 2015-12-07 | 2017-06-15 | Proximagen Limited | Vap-1 inhibitors for treating pain |
| BR112019013963A2 (pt) * | 2017-01-09 | 2020-04-28 | Ardelyx Inc | inibidores de antiporte mediado por nhe |
| CA3110877A1 (en) * | 2018-08-27 | 2020-03-05 | Spinogenix, Inc. | Fascin binding compounds for spinogenesis |
| CN113939510A (zh) | 2019-05-29 | 2022-01-14 | 先正达农作物保护股份公司 | 杀微生物衍生物 |
| IL293965A (en) | 2019-12-19 | 2022-08-01 | Janssen Pharmaceutica Nv | History of Spiro straight chain transformed |
| EP4136076A1 (en) * | 2020-04-16 | 2023-02-22 | F. Hoffmann-La Roche AG | Biphenyl derivatives |
| US20230250096A1 (en) | 2021-06-01 | 2023-08-10 | Janssen Pharmaceutica Nv | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES |
| WO2023193790A1 (en) * | 2022-04-08 | 2023-10-12 | Janssen Pharmaceutica Nv | Crystalline forms of an inhibitor of the menin/mll interaction |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| DE19649460A1 (de) | 1996-11-26 | 1998-05-28 | Bayer Ag | Neue substituierte Pyrazolderivate |
| CZ2002898A3 (cs) | 1999-09-14 | 2002-07-17 | Aventis Pharmaceuticals Inc. | Benzisoxazolyl-, pyridoisoxazolyl- a benzthienylfenoxyderiváty a jejich pouľití jako antagonistů D4 |
| WO2002038153A1 (en) * | 2000-11-09 | 2002-05-16 | Biovitrum Ab | New use of 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine derivatives |
| US6982286B2 (en) | 2001-07-12 | 2006-01-03 | Biotie Therapies Corp. | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| AU2002341920A1 (en) | 2001-10-02 | 2003-04-14 | Smithkline Beecham Corporation | Chemical compounds |
| US7456169B2 (en) | 2003-02-27 | 2008-11-25 | Abbott Laboratories Inc. | Heterocyclic kinase inhibitors |
| US20050096360A1 (en) | 2003-08-08 | 2005-05-05 | Salter-Cid Luisa M. | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment of diseases |
| CN103788089A (zh) | 2003-09-17 | 2014-05-14 | 詹森药业有限公司 | 作为血清素受体调节剂的稠合杂环化合物 |
| EP1730148A4 (en) | 2004-02-03 | 2009-08-19 | Abbott Lab | USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| EP1874769B1 (de) | 2005-04-25 | 2011-09-14 | Merck Patent GmbH | Neuartige aza-heterozyklen als kinase-inhibitoren |
| SI1906965T1 (sl) | 2005-06-22 | 2015-09-30 | Chemocentryx, Inc. | Azaindolne spojine in postopki uporabe |
| EP2004166A2 (en) | 2006-03-31 | 2008-12-24 | La Jolla Pharmaceutical Company | Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases |
| AU2007234408B2 (en) | 2006-04-04 | 2011-05-19 | Fibrogen, Inc. | Pyrrolo- and thiazolo-pyridine compounds as HIF modulators |
| GB0610242D0 (en) | 2006-05-23 | 2006-07-05 | Novartis Ag | Organic compounds |
| US20100099673A1 (en) | 2007-01-17 | 2010-04-22 | Bilodeau Mark T | Decahydroquinoline analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| CA2683821A1 (en) | 2007-05-02 | 2008-11-13 | Novartis Ag | Heterocyclic compounds and their use as pesticides |
| GB0725103D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
| CA2712701A1 (en) | 2008-01-31 | 2009-08-06 | Henning Steinhagen | Cyclic azaindole-3-carboxamides, their preparation and their use as pharmaceuticals |
| WO2009108551A2 (en) | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
| CA2737527C (en) | 2008-09-16 | 2015-12-29 | Proximagen Limited | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds useful as inhibitors of ssao activity |
| WO2010031791A1 (en) | 2008-09-16 | 2010-03-25 | Biovitrum Ab (Publ) | New compounds ii |
| DK2376490T3 (da) * | 2008-12-04 | 2013-04-15 | Proximagen Ltd | Imidazopyridinforbindelser |
| JP2012211085A (ja) | 2009-08-12 | 2012-11-01 | Kyowa Hakko Kirin Co Ltd | ヘッジホッグシグナル阻害剤 |
| GB201004311D0 (en) * | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
| GB201115853D0 (en) | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
-
2011
- 2011-09-14 CA CA2847193A patent/CA2847193A1/en not_active Abandoned
- 2011-09-14 EA EA201490451A patent/EA201490451A1/ru unknown
- 2011-09-14 AU AU2011376717A patent/AU2011376717A1/en not_active Abandoned
- 2011-09-14 EP EP11761040.2A patent/EP2755974A1/en not_active Withdrawn
- 2011-09-14 IN IN1883DEN2014 patent/IN2014DN01883A/en unknown
- 2011-09-14 US US14/344,417 patent/US9150574B2/en not_active Expired - Fee Related
- 2011-09-14 CN CN201180073402.9A patent/CN103889983B/zh not_active Expired - Fee Related
- 2011-09-14 JP JP2014530103A patent/JP5796130B2/ja not_active Expired - Fee Related
- 2011-09-14 WO PCT/EP2011/065967 patent/WO2013037411A1/en not_active Ceased
- 2011-09-14 BR BR112014005793A patent/BR112014005793A2/pt not_active IP Right Cessation
- 2011-09-14 SG SG11201400277VA patent/SG11201400277VA/en unknown
-
2014
- 2014-03-06 IL IL231353A patent/IL231353A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL231353A0 (en) | 2014-04-30 |
| JP2015502913A (ja) | 2015-01-29 |
| CN103889983A (zh) | 2014-06-25 |
| IN2014DN01883A (enExample) | 2015-05-15 |
| US20140357623A1 (en) | 2014-12-04 |
| EP2755974A1 (en) | 2014-07-23 |
| SG11201400277VA (en) | 2014-05-29 |
| CN103889983B (zh) | 2015-12-09 |
| US9150574B2 (en) | 2015-10-06 |
| JP5796130B2 (ja) | 2015-10-21 |
| EA201490451A1 (ru) | 2014-12-30 |
| CA2847193A1 (en) | 2013-03-21 |
| WO2013037411A1 (en) | 2013-03-21 |
| AU2011376717A1 (en) | 2014-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014005793A2 (pt) | compostos inibidores de enzimas | |
| NZ602141A (en) | Inhibitors of semicarabazide-sensitive amine oxidase | |
| RU2018115722A (ru) | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ | |
| PH12015500275A1 (en) | Salts and solid forms of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same | |
| MX2008008405A (es) | Metodos para tratar lupus cutaneo usando compuestos de aminoisoindolina. | |
| WO2014028445A3 (en) | Cereblon isoforms and their use as biomarkers for therapeutic treatment | |
| AR070936A1 (es) | 1,2,4 -triazoles trisustituidos | |
| AR057467A1 (es) | Sales de 4- metil-n-(3-(4-metilimidazol-1-il)-5- trifluorometil- fenil)-3- (4- metil- imidazol-1-il)-5- trifluorometil - fenil)-3-(4- piridin -3- il pirimidin-2- lamino ) - benzamida. metodo de preparacion y composiciones farmaceuticas | |
| JO3308B1 (ar) | أشكال بلورية من 4-ميثيل-ان-[3-(4-ميثيل-اميدازول-1-واي ال)-5-ترفلوروميثيل-فينيل]-3-(4-بيريدين-3-واي ال-بيريميدين-2-يلامينو)-بنزاميد | |
| CL2014000534A1 (es) | Procesos para preparar {1-{1-[3-fluoro-2-(trifluorometil)isonicotinoil]piperidin-4-il}-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo y compuestos intermediarios, inhibidores de jak; y compuesto intermediario (3-fluoro-2-(trifluorometil)piridin-4-il)(1,4-dioxa-8-azaspiro[4,5]decan-8-il)metanona. | |
| NZ630488A (en) | Piperidine derivatives for gpr119 agonist | |
| CY1115376T1 (el) | Βελτιωμενη μεθοδος | |
| WO2011024072A3 (en) | Hybrid polypeptides including meningococcal fhbp sequences | |
| NZ592792A (en) | Heterocyclically substituted aryl compounds as hif inhibitors | |
| WO2009104097A3 (en) | Meningococcal fhbp polypeptides | |
| NZ594765A (en) | Anthelmintic agents and their use | |
| WO2009017455A1 (en) | A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor | |
| DK2076506T3 (da) | Heterocyklisk substituerede piperidiner som ORL-1-ligander | |
| PE20141370A1 (es) | Inhibidores de quinasa | |
| TN2012000247A1 (en) | 4-[2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine salts | |
| EA201001334A1 (ru) | Твёрдый препарат гидрохлорида карипразина для перорального введения | |
| NZ602289A (en) | Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias | |
| NZ594556A (en) | Carboxamide compounds and methods for using the same | |
| AR044821A1 (es) | 4-(aminometil)-piperidin benzamidas como antagonistas de 5ht4 | |
| RU2013102399A (ru) | Производные (3-метилпирролидин-3-ил)-метил пиридинилового эфира и их применение в качестве антагонистов рецептора nk-3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |